coli isolates collected longitudinally from two LRS114688 subjects confirms that GSK2251052 resistance is due to specific mutations, selected on the first day of therapy, in the LeuRS editing domain. Phylogenetic analysis strongly suggests that resistant Escherichia coli isolates resulted from clonal expansion of baseline susceptible strains. This resistance development likely resulted from the confluence of multiple factors, of which only some can be assessed pre-clinically. Our study shows the challenges of developing antibiotics and the importance of clinical studies to evaluate their effect on disease pathogenesis.
INTRODUCTION

1
Approximately 5% of patients admitted to hospitals in the United States develop nosocomial 2 infections that increase not only patient mortality (1) but also hospitalization time and cost of In both studies, 210 subjects at least 18 years old were to be treated for ≥5 -≤14 days.
43
Subjects in the cUTI Study LRS114688 were randomized (1:1:1) to receive GSK2251052 44 750 mg or 1500 mg BID, or imipenem-cilastatin 500 mg every 6 hr. Twenty subjects had 45 been enrolled when this study was terminated, 14 of them having received BID doses of 46 GSK2251052 at 750 mg (6) or 1500 mg (8). Nineteen of the 20 subjects had a qualifying 47 Gram-negative uropathogen at baseline, with E. coli being the most frequently isolated (18 of 48 26 isolates). Subjects in the cIAI Study LRS114689 were randomized (1:1:1) to receive 49 GSK2251052 750 mg or 1500 mg BID, or meropenem 1 g TID. Fifteen subjects had been 50 enrolled when this study was terminated, nine of them having received BID doses of 51 GSK2251052 at 750 mg (5) or 1500 mg (4). Ten of the 15 subjects had a confirmed Gram-52 negative pathogen at baseline, with E. coli being the most frequently isolated (9 of 28 53 isolates).
54
The institutional review board reviewed and approved the studies prior to subject 55 enrolment. Written informed consent was obtained from each subject prior to the 56 performance of any study-specific procedures. strain. The total number of resistant colonies was extrapolated from this representative set.
77
Frequency of resistance was calculated by dividing the total number of resistant colonies by 78 the total number of CFUs plated.
79
Genetic characterization of isolates with reduced susceptibility to GSK2251052.
80
The PCR primers used for DNA amplification were designed from the appropriate regions of 
RESULTS
145
Phase II clinical trials with GSK2251052. Twenty subjects, 14 of whom received
146
IV BID doses of GSK2251052, were enrolled in Study LRS114688 when Gram-negative
147
isolates with reduced susceptibility to GSK2251052 were recovered from four subjects (202, 148 203, 252 and 751) ( Table 1 ) and, as a consequence, the study was terminated. Three of these 149 four subjects demonstrated a significant increase (>32-fold) in GSK2251052 MIC between and two subjects, 203 and 252, received doses of 750 mg for 6 and 14 days, respectively.
152
The fourth subject (751) had different pathogens isolated at baseline and post-baseline and 153 had received 1500 mg doses for 6 days. 
172
Definitive conclusions regarding safety and/or efficacy of GSK2251052 could not be 173 made in either study due to the limited number of subjects enrolled at the time of early termination.
175
Characterization of clinical isolates with reduced GSK2251052 susceptibility. (Tables 1 and 2 ).
209
In both subjects, nonsynonymous (NS) codon changes mostly occurred by Day 2 and 210 were retained over subsequent time points (Fig. 1a,b ) with the exception of subject 252 E. Tables 2 and 3) Table 2 ).
221
Fewer amino acid changes were observed in isolates from subject 202 relative to 222 baseline blood organism ( Fig. 1b; Table 3 ). In addition to the NS changes in LeuRS,
223
mutations were seen in several hypothetical genes, a transposase, and a prophage gene.
224
Some changes, such as those in AtpF (ATP synthase F 0 F 1 subunit B) and RnfC (electron 225 transport protein), were specific to the baseline urine isolate.
226
Phylogenetic trees based on nucleotide sequences of either multi-locus sequencing 227 type (MLST) or SNV genes showed that E. coli isolates were more similar within subjects 228 than between subjects (Fig. 2a,b) , suggesting that they were highly clonal and no new re- 
